Tempest Therapeutics (TPST) to Release Quarterly Earnings on Tuesday

Tempest Therapeutics (NASDAQ:TPST) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Tempest Therapeutics to post earnings of ($0.28) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Monday, March 30th. The company reported ($0.62) EPS for the quarter, hitting the consensus estimate of ($0.62). On average, analysts expect Tempest Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempest Therapeutics Stock Down 1.7%

Shares of NASDAQ TPST traded down $0.04 during midday trading on Tuesday, hitting $2.08. 45,397 shares of the company’s stock were exchanged, compared to its average volume of 179,146. Tempest Therapeutics has a 12 month low of $1.50 and a 12 month high of $12.23. The company’s 50 day moving average price is $2.01 and its 200 day moving average price is $3.84. The firm has a market capitalization of $29.76 million, a PE ratio of -0.32 and a beta of -1.75.

Insider Activity

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the firm’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer directly owned 231,482 shares in the company, valued at approximately $500,001.12. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.28% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned approximately 0.23% of Tempest Therapeutics as of its most recent SEC filing. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen upgraded Tempest Therapeutics to a “hold” rating in a research note on Saturday, April 18th. Zacks Research upgraded Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Tempest Therapeutics currently has a consensus rating of “Moderate Buy”.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.